Random Trial for Elderly Patients With NSCLC

Inje University

Overview

1. Recently a radomized trial of vinorelbine versus best supportive care in patients at 70 years of age or older demonstrated a definite improvement in overall survival rate and quality of life with chemotherapy. 2. The role of combination therapy containing the platinum compound, which is the standard therapy for the young patients is still vague. 3. Gemcitabine and carboplatin have favorable toxicity profile.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Non-Small Cell Lung Cancer

Interventions

vinorelbine, gemcitabine and carboplatinDRUG

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with pathologically confirmed, advanced(clinical stage IIIB or IV) NSCLC * No previous chemotherapy history * Age ≥ 65 years * ECOG performance status ≤ 2 * Adequate marrow function (ANC ≥ 2,000/mm3, platelet ≥ 100,000/mm3), renal and liver function (total bilirubin \< 2.0 mg/dL, AST/ALT levels \< 3 × the upper limit of normal, serum creatinine \< 2.0 mg/dL) * Patients with informed written consent Exclusion Criteria: * Patients with other major illness(active infection, severe heart disease, concomitant malignancy, etc)

Locations (1)

Inje University Sanggyepaik Hospital

Seoul, South Korea

RECRUITING

Central Contacts

Young Jin Yuh, M.D.

CONTACT

82-2-950-1460 yjyuh@sanggyepaik.ac.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.